GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company developing immune-oncology therapies built on its proprietary TriKE® and Dual Targeting TriKE® platforms. Its programs are designed to harness a patient’s natural killer cells to attack cancer, but the company remains pre-commercial and dependent on financing to fund development.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueMulti-specific biologic drug candidates designed to activate natural killer cells against cancer.
Next-generation platform programs that target two cancer-related antigens while engaging NK cells.
Internal discovery, translational work, and clinical development activities supporting the pipeline.
Customers
GT Biopharma does not sell a commercial product base today; its primary stakeholders are clinical investigators, research collaborators, regulators, and future oncology treatment providers. If approved, its therapies would be used by hospitals, cancer centers, and physicians treating patients with difficult-to-treat malignancies.
Academic and clinical partners that support translational research, trial execution, and data generation for the pipeline.
FDA and comparable agencies that review safety, efficacy, manufacturing, and labeling before commercialization.
Hospitals, cancer centers, and oncologists that would prescribe or administer approved therapies.
Patients with malignancies that may be eligible for NK-cell engaging immuno-oncology treatments.
Strategy
GT Biopharma’s strategy is centered on advancing its TriKE® and Dual Targeting TriKE® platforms through development and toward regulatory approval. The company’s near-term priority is preserving liquidity and securing additional financing so it can continue clinical and preclinical work without interruption.
The company disclosed substantial doubt about its ability to continue as a going concern without new capital.
Pipeline progress is the main value driver for a pre-commercial biotech.
Platform protection is critical to differentiation and future partnering or commercialization.
Geography
The company is headquartered in the United States and operates as a U.S.-based clinical-stage biotech. The filings provided do not disclose meaningful country-by-country revenue, which is consistent with a development-stage company that has not yet built a commercial sales footprint.
Risks
The company faces classic clinical-stage biotech risks: financing dependence, regulatory uncertainty, and the possibility that its platform never reaches commercialization. Its disclosures also highlight competition from better-capitalized biotech and pharmaceutical companies, plus operational risks tied to cybersecurity, supply chain, and FDA compliance.
- Going concern and liquidity shortfallImpact: CriticalLikelihood: High
Management stated existing cash may not fund operations for one year without additional financing.
Exposure - Clinical development and regulatory failureImpact: HighLikelihood: High
Product candidates may not demonstrate safety or efficacy, and approvals are uncertain.
Exposure: Pipeline programs and future commercialization
- Competition from larger biotech and pharma companiesImpact: HighLikelihood: High
Competitors have greater capital, manufacturing, and regulatory resources.
Exposure - Intellectual property compromiseImpact: HighLikelihood: Low
Loss or weakening of IP protection could reduce exclusivity and partnering value.
Exposure: TriKE® platform and related therapeutics
- FDA and post-approval complianceImpact: MediumLikelihood: Low
Even approved products remain subject to manufacturing, labeling, and surveillance requirements.
Exposure: Future approved products and clinical operations
Accounting
Judgemental itemsManagement disclosed substantial doubt about continuing operations without new financing.
Impact: Affects financial statement basis and investor assessment of solvency
The company recorded a warrant liability, which must be remeasured at fair value.
Impact: Can create periodic non-cash gains or losses
Capital-raising costs are capitalized until financing closes or are expensed if abandoned.
Impact: Affects current assets and equity transaction accounting
Cash constraints make estimates and timing of vendor obligations important.
Impact: Can materially affect current liabilities and liquidity presentation
Similar listed companies
Publicly listed companies with a comparable business focus.
Grace Therapeutics, Inc.
GRCE · Pharmaceutical Preparations
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Nkarta, Inc.
NKTX · Pharmaceutical Preparations
Marker Therapeutics, Inc.
MRKR · Pharmaceutical Preparations
Mustang Bio, Inc
MBIO · Pharmaceutical Preparations
Greenwich LifeSciences, Inc.
GLSI · Pharmaceutical Preparations
Last updated: 24/09/2026